Apatinib for fluid buildup in the belly from cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a pill called apatinib in people whose cancer has spread to the belly and causes fluid to build up (malignant ascites). Apatinib works by cutting off the blood supply that tumors need to grow, which may help reduce the fluid and ease symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have persistent fluid in the belly that is confirmed to contain cancer cells, and standard treatments (like chemotherapy) have not helped.
- You have had at least two procedures to drain the fluid and have tried water pills (diuretics) within the past 60 days.
- You are not already taking or planning to take other cancer treatments (like chemotherapy, immunotherapy, or radiation) during the trial.
- You have not had certain types of cancer drugs (called anti-angiogenic agents) within the past 60 days.
- Your heart, liver, kidneys, and blood counts are within acceptable limits, and you are generally able to care for yourself (ECOG performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called apatinib as a first treatment for older adults with advanced stomach or gastroesophageal junction cancer. It might help if you cannot or do not want to have chemotherapy.
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This study tests whether adding the drug apatinib mesylate to your doctor's chosen treatment can help slow or shrink advanced breast cancer. It's for people whose cancer has continued to grow despite prior hormonal therapy and CDK4/6 inhibitor treatment.
This trial tests a combination of two oral drugs, TAS-102 and apatinib, as a third-line treatment for advanced stomach cancer. It aims to see if this combination can help control the cancer when other treatments have not worked.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.